The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.50
Bid: 63.00
Ask: 66.00
Change: 1.00 (1.57%)
Spread: 3.00 (4.762%)
Open: 63.00
High: 66.50
Low: 61.50
Prev. Close: 63.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM & Board Changes

29 Jun 2023 11:04

RNS Number : 3975E
NetScientific PLC
29 June 2023
 

For immediate release

NetScientific plc

("NetScientific", "Group" or the "Company")

Result of Annual General Meeting and Board Changes

NetScientific plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that all resolutions set out in the 2023 Notice of Annual General Meeting sent to shareholders were duly passed at the Company's Annual General Meeting held earlier today.

Result of Annual General Meeting

Resolutions 1 to 9 were passed as Ordinary Resolutions and Resolution 10 was passed as a Special Resolution. The proxy voting results are as follows:

 

Resolution

For

%

Against

%

Vote Total

Vote Total as % of Issued Share Capital

Withheld*

1. To receive and adopt the Company's Annual Report and Accounts for the period ended 31 December 2022

6,910,987

100%

686

0%

6,911,673

29%

-

2. To receive and approve the Directors' Remuneration Report

6,871,686

99%

39,975

1%

6,911,661

29%

12

3. To reappoint BDO LLP as auditors for the forthcoming year

6,873,987

99%

37,686

1%

6,911,673

29%

-

4. To authorise Audit Committee in determining Auditors' remuneration

6,910,987

100%

686

0%

6,911,673

29%

-

5. To confirm the reappointment of Dr Ilian Iliev as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

6. To confirm the reappointment of Edward Hooper as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

7. To confirm the reappointment of Dr Jonathan Robinson as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

8. To confirm the reappointment of Dr Charles Spicer as a director

6,897,104

100%

6,075

0%

6,903,179

29%

8,494

9. To authorise the Directors to allot relevant securities pursuant to section 551 of the Companies Act 2006

6,865,004

99%

46,669

1%

6,911,673

29%

-

10. To disapply pre-emption rights on the allotment of securities or sale of treasury shares in connection with a pre-emptive offer or on allotment of shares

6,810,004

99%

101,669

1%

6,911,673

29%

-

 

* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

Board Changes

Further to the announcement made on 3 April 2023, Prof Stephen Smith has retired from the NetScientific Board with effect from the closing of the AGM. It is anticipated that he will remain an adviser to a number of the Group's life sciences portfolio companies.

Further to the announcement made on 31 May 2023, Dr Charles Spicer has taken over as Chair with effect from the closing of the AGM. Dr Jonathan Robinson has retired as Interim Chair and moves to the role of Senior Independent Director.

Dr Ilian Iliev, Chief Executive Officer of the Company, commented:

"On behalf of the Company and the Board, I extend a warm welcome to Charles as he joins our team. We are looking forward to working with him and benefiting from his expertise. Additionally, I would like to express my appreciation to Prof. Stephen Smith for his dedicated service since 2016. We greatly value his ongoing counsel and understanding of the life sciences sector. Finally, I would like to extend my gratitude to Jonathan Robinson for his interim board leadership. We look forward to continuing to work alongside him in his new role as Senior Independent Director."

Dr Charles Spicer, Chair of the Company, commented:

"I am excited by the future prospects of the Company and eagerly anticipate working with Ilian and the wider team. Our primary objective will be to drive shareholder returns through profitable exits and strategic expansion of our portfolio."

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGCGDLCUDDGXC
Date   Source Headline
29th Mar 20187:00 amRNSProposed Placing and Subscription
29th Mar 20187:00 amRNSFull Year Results
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription
24th May 20177:00 amRNSVortex Initiates Clinical Research Studies
10th May 20177:00 amRNSProAxsis announces additional IP
5th May 20177:00 amRNSProAxsis Presents New Data at Major US Conference
24th Apr 20177:00 amRNSBTG purchases Wanda's shares in Oncoverse
3rd Apr 20177:00 amRNSFull Year Results for the year ended 31 Dec 2016
31st Mar 20177:00 amRNSVortex Biosciences Announces Publications
27th Mar 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSVortex Biosciences Launches VTX-1 Liquid Biopsy
15th Feb 20177:00 amRNSVortex Biosciences' CSO Wins SLAS Innovation Award
9th Feb 20177:00 amRNSVortex Biosciences' CSO Finalist for SLAS Award
30th Jan 20177:00 amRNSGrant of Options to Directors
20th Dec 20167:00 amRNSNew CEO appointed to Wanda
16th Dec 20167:00 amRNSExecuted Warrants
18th Nov 20167:00 amRNSNetscientific: Vortex Biosciences Analysis Data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.